Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Return on Sales (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Return on Sales for 15 consecutive years, with 4.78% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales rose 559.0% year-over-year to 4.78%; the TTM value through Mar 2026 reached 6.41%, down 2431.0%, while the annual FY2025 figure was 7.64%, 2610.0% down from the prior year.
  • Return on Sales hit 4.78% in Q1 2026 for Agios Pharmaceuticals, up from 5.41% in the prior quarter.
  • Across five years, Return on Sales topped out at 105.75% in Q3 2024 and bottomed at 14.71% in Q1 2023.
  • Average Return on Sales over 5 years is 1.26%, with a median of 9.02% recorded in 2025.
  • Year-over-year, Return on Sales soared 11809bps in 2024 and then plummeted -11378bps in 2025.
  • Agios Pharmaceuticals' Return on Sales stood at 0.4% in 2022, then plummeted by -3490bps to 13.51% in 2023, then soared by 33bps to 9.0% in 2024, then skyrocketed by 40bps to 5.41% in 2025, then rose by 12bps to 4.78% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 4.78%, 5.41%, and 8.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.